Highlights in breast cancer
|
|
- Virginia Brown
- 5 years ago
- Views:
Transcription
1 CONGRESS HIGHLIGHTS SPECIAL EDITION 309 Highlights in breast cancer W. Lybaert, MD In this article, the most important new studies presented at ESMO 2017 in Madrid in early (EBC) and metastatic breast cancer (MBC) are summarised. In EBC, 5 topics are highlighted: integration of PI3K and CDK4/6 inhibition in the neoadjuvant treatment of oestrogen receptor positive (ER+) EBC, dual endocrine blockade as adjuvant treatment in ER+ EBC, escalated adjuvant treatment in human epidermal growth factor receptor positive (HER2+) EBC and small tumours that can also show an aggressive course. In MBC, 4 topics are discussed: predicting immunogenicity in MBC, abscopal effect in MBC, confirmed benefit of PARP inhibitors in BRCA mutated MBC and CDK4/6 inhibition in first-line MBC. (BELG J ONCOL 2017;11(7): ) EARLY BREAST CANCER PRIMARY RESULTS OF THE LORELEI-STUDY: A PHASE II RANDOMISED, DOUBLE-BLIND STUDY OF NEOADJUVANT LETROZOLE + TASELISIB VERSUS LETROZOLE + PLACEBO IN POSTMENOPAUSAL WOMEN WITH ER+/HER2EARLY STAGE BREAST CANCER Taselisib is an oral, potent and selective PI3K inhibitor with enhanced activity against PIK3CA mutant (MUT) cancer cells. Confirmed partial responses were observed in patients (pts) with PIK3CA MUT MBC treated with taselisib as a single agent and combined with endocrine therapy. Three hundred and thirty four postmenopausal pts with ER+/HER2-, stage I-III, operable EBC and evaluable tumour tissue for centralised PIK3CA genotyping were randomised (1:1) to receive letrozole + either taselisib (4 mg five days on/ two days off) or placebo for sixteen weeks (wks), followed by surgery. Co-primary endpoints were objective response rate (ORR) by centrally assessed breast MRI and pathologic complete response (pcr, ypt0/is N0) rate at surgery, in all randomised pts and in pts with PIK3CA MUT tumours. The addition of taselisib to letrozole increased the ORR from 38% to 56.2% in the PIK3CA MUT subset (p = 0.033) and in all randomised ptsfrom 39.3% to 50% (p = 0.049). No sig- nificant difference was observed for pcr rate overall or in the PIK3CA MUT pts. The most common grade 3-4 adverse events in the taselisib arm were gastrointestinal disorders (7.8%), infections (4.8%) and skin/subcutaneous tissue disorders (4.8%). Grade 3-4 hyperglycaemia occurred in 1.2% of pts. Taselisib discontinuation (10.8%) and dose reductions (11.4%) were infrequent.1 LORELEI is the first randomised study to demonstrate a significant increase in ORR following treatment with a PI3K selective inhibitor + letrozole in patients with ER+/HER2- EBC. Comments on this study are an expected low pcr rate with only four months of endocrine therapy with or without addition of taselisib, and that the addition of taselisib added mostly toxicity on a background of increased ORR. In conclusion, pan-pi3k inhibitors are not ready for prime-time in ER+ EBC. LETROZOLE AND PALBOCICLIB VERSUS 3RD GENERATION CHEMOTHERAPY AS NEOADJUVANT TREATMENT OF LUMINAL BREAST CANCER: RESULTS OF THE PHASE II UNICANCERNEOPAL STUDY The benefit of neoadjuvant chemotherapy in pts with luminal breast cancer (LBC) is limited. Palbociclib combined with endocrine treatment has shown impressive results in Department of Medical Oncology, AZ Nikolaas Sint-Niklaas (Iridium Kankernetwerk), Sint-Niklaas, Belgium. Please send all correspondence to: W. Lybaert, MD, AZ Nikolaas Sint-Niklaas, Department of Medical Oncology, Moerlandstraat 1, 9100 SintNiklaas, Belgium, willem.lybaert@aznikolaas.be. Conflict of interest: The author has nothing to disclose and indicates no potential conflict of interest. Keywords: breast cancer, luminal, early breast cancer, metastatic breast cancer, PI3K, CDK4/6, neoadjuvant, HER2, immunogenicity, PARP, BRCA VO LU M E11N O V E M B E R
2 310 MBC. In this trial, postmenopausal women were eligible if they had stage II-III ER+/HER2- EBC, were not a candidate for breast conserving surgery (BCS), and had either a PAM50 luminal B, or a PAM50 luminal A profile with proven lymph node involvement (N+). A parallel 1:1 randomisation proposed six courses of 3 rd generation chemotherapy (FEC100 x3 - docetaxel 100 x3), or 19 wks of letrozole (L) 2.5 mg/day + palbociclib (P) 125 mg/day, 3 wks/4. Surgery was performed at week 20. The primary endpoint was locally assessed Residual Cancer Burden (RCB) rate. Secondary endpoints included safety, response rate, positive and negative predictive values of PAM50 ROR (risk of recurrence)-defined status, centrally reviewed RCB, and BCS rates. Out of 184 screened pts, 106 women with stage II-IIIA, PAM50-ascertained LBC were randomised. Pts had T1-2 (73%) or T3 (27%), N+ (26.5%), and luminal B (89%) tumours. Local RCB 0/I/II/III was observed in 3.8%/3.8%/52%/40.4% of pts in the LP arm, and in 5.9%/9.8%/37.3%/47.1% in the chemo arm, respectively. Central and local RCB results were identical. ROR score was not predictive of RCB 0/I. The ORR and BCS rates were 74.5% and 76%, and 69.2% and 68.6%, in the LP and chemo arms, respectively. The Ki-67 final median value was significantly lower in the LP arm (3% versus 8%). Of 19 serious adverse events, two occurred in the LP arm and seventeen in the chemo arm. 2 Neoadjuvant LP led to a slightly lower pcr/rcb 0/I rate than chemo, however clinical response and BCS rates were similar in both arms and LP had a more favourable safety profile. This is the first head-to-head comparison of endocrine therapy with a CDK4/6 inhibitor and chemotherapy. The study did not meet its primary endpoint (RBC) for letrozole + palbociclib versus chemotherapy. The challenge remains the identification of luminal EBC pts for whom an endocrine-based approach can improve the outcome, either replacing chemotherapy in intermediate-risk or as an add-on in high-risk disease. The potential of this scheme may lie in frail and elderly pts. PHASE III STUDY EVALUATING THE ADDITION OF FULVESTRANT TO ANASTROZOLE AS ADJUVANT THERAPY IN POSTMENOPAUSAL WOMEN WITH HR+/HER2- EBC: GEICAM Fulvestrant (F) is a selective oestrogen receptor degrader for HR+ MBC pts. This trial compares anastrozole (A) versus A in combination with F (A+F) to address the hypothesis that a complete oestrogen blockade can prevent resistance to aromatase inhibitors in the adjuvant setting. 3 This was a multicentre, open label, phase III study in which HR+/HER2- EBC postmenopausal pts were randomised 1:1 to A for five years (y) or A+F (A concurrently with F 250 mg/4 weeks for 3y followed by 2y of A). Pts were stratified for prior chemotherapy (yes/no), number of positive lymph nodes (0/1-3/ 4), HR status (both positive/one positive) and site. The primary objective was disease-free survival (DFS). In 2010, when the negative results of the FACT trial were reported, the financer decided to stop study support after the inclusion of 872 pts. Four hundred and thirty seven pts were randomised to A and 435 to A+F. Pts characteristics were well balanced between arms; median age was 62y, 46.9% were N0, 89.5% ER+/PgR+ and 68.2% had received prior chemotherapy. Treatment was completed as planned by 72.5% and 48.5% of A and A+F pts. Most relevant grade 2-3 toxicities with A versus A+F were hypertension (13.2%; 9.9%), fatigue (5.2%; 11.8%), LDL-cholesterol increase (9.4%; 5.3%), osteoporosis (5.5%; 6.9%) and musculoskeletal bone/joint pain (26.3%; 29.4%). After a median follow-up of 6.3y, the proportion of pts disease-free at 5y was 90.99% (A 90.77%, A+F 91.25%, p = 0.357); 9.4% had BC relapse (A 10.5%; A+F 8.3%) and 4.3% had secondary tumours (A 3.9%; A+F 4.6%). The medians for survival and breast cancer-specific survival were not reached. 3 This study failed to demonstrate a statistically significant increase in DFS of adding F to A as adjuvant therapy, though no formal conclusion can be extracted from this trial due to the F administered dose (250 mg) and the actual trial sample size. Inclusion of only high-risk pts with the appropriate dose of F (500 mg) is a missed opportunity to find a benefit of dual endocrine blockade. NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER (BC): 5-YEAR ANALYSIS OF THE PHASE III EXTENET TRIAL In the Herceptin Adjuvant (HERA) trial, 24% of pts who received trastuzumab (T) for 1y had a disease recurrence at 11y of follow-up. The primary analysis of the ExteNET trial, performed after 2y of follow-up, showed that a 1y course of neratinib after T-based adjuvant therapy significantly improved the invasive disease-free survival (idfs) versus placebo in HER2+ EBC. 4 During ESMO 2017, updated 5y efficacy findings were reported. 5 ExteNET is an international, multicentre, randomised, double-blind, placebo-controlled phase III trial. Pts received oral neratinib 240 mg/day or placebo for 1y. After 2y, randomised pts were asked to reconsent to collection of data concerning disease recurrences and survival from medical records for a further 3y. The pre-planned 5y analysis was by intention-to-treat (ITT). Non-consenting pts were censored at their last physical examination. The updated 5y efficacy findings were based on 2,840 pts in the ITT pop- VOLUME11NOVEMBER2017
3 CONGRESS HIGHLIGHTS SPECIAL EDITION 311 ExteNET: idfs by hormone receptor status FIGURE 1. idfs in function of the hormone receptor status in the ExteNET study. 5 ulation (1,420 pts receiving neratinib and 1,420 receiving placebo). Of these, 53 pts had died during the initial 2y follow-up and 2,117 (76%) pts consented to the additional follow-up. Overall, 1,209 pts were HR-including 88.8% and 88.9% of pts in the neratinib and placebo arms, respectively. After a median follow-up of 5.2y, 2,810 pts in the ITT population demonstrated idfs rates of 90.2% with neratinib versus 87.7% with placebo (HR: 0.73, p= 0.008). The HR+ subgroup demonstrated idfs rates of 91.2% with neratinib versus 86.8% with placebo (HR: 0.60, p= 0.002); while the HR- subgroup showed idfs rates of 88.9% versus 88.8% (HR: 0.95, p= 0.762). Overall survival data are not yet mature. Neratinib was associated with a transient initial decrease in HRQoL, particularly regarding physical well being, that may have been due to neratinib-related diarrhoea. ExteNET showed a continued clinically significant benefit of neratinib, particularly in higher risk, HR+ disease (Figure 1). Diarrhoea is a limiting factor, but can be reduced significantly with prophylaxis, which is mandatory a component of treatment. There is no evidence of increased symptomatic cardiac toxicity. 5,6 NOT ALL SMALL NODE NEGATIVE (PT1A/BN0) BREAST CANCERS ARE SIMILAR: OUTCOME RESULTS FROM AN EORTC 10041/BIG 3-04 (MINDACT) TRIAL SUBSTUDY Adjuvant systemic therapy for pt1a/bn0 breast cancer is controversial, as these tumours overall have low relapse risks. The best tool to identify a subgroup that would benefit from adjuvant treatment, is unknown. This subgroup included pts with pt1a/bn0 tumours enrolled in MINDACT who had both their genomic risk G (per MammaPrint ) and clinical risk C (per a modified version Adjuvant! Online) assessed. Pts characterised as lowrisk in both assessments were spared chemotherapy (CT), while in those characterised as C&G high, CT was advised. Discordant cases were randomised to receive CT based on the C or the G result. Here, we report the 5y rates of distant metastasis-free survival (DMFS), distant metastasis-free interval (DMFI) and overall survival (OS) for pt1a/bn0 pts who received or not CT based on their G or C risk result. 7 Eight hundred and twenty six of 6,693 (12.3%) pts with pt1a/bn0 tumours were enrolled in MINDACT. Three hundred and ten of 826 (37.5%) were 60 years and 525/826 (63.6%) were postmenopausal. Five hundred and eighty five of 727 (80.5%) were invasive ductal, 662/727 (91.1%) ER+, 46/727 HER2+ (6.3%) and 81/727 (11.1%) had grade 3 tumours. IHC subtype classification identified 426/727 (58.6%) as luminal A; 193/727 (26.5%) luminal B; 38/727 (5.2%) luminal B/HER2+; 8/727 (1.1%) HER2+; 37/727 (5.1%) triple-negative tumours. Almost all pts (820/826; 99.3%) were clinical low-risk (CL). Overall, 624/826 (75.5%) were CL/GL and 196/826 (23.7%) were CL/GH (five patients were CH/GL, no cases were CH/GH, one missing). Five year VOLUME11NOVEMBER20177
4 312 DMFS for pts with CL/GH pt1a/bn0 tumours who received CT was 97.3% versus 91.4% for those who did not. Five year DMFI and OS for these pts treated with CT were 98.8% and 98.5% versus 91.4% and 95.8%, respectively, for those who did not receive CT. 7 Biological characteristics can be used as determinants of adjuvant CT administration for T1a/bN0 tumours. An important portion (23.7%) of these small tumours was CL and GH (MammaPrint ) risk and derived a benefit from CT. The majority of these cases were also luminal B, HER2+ or basal. Given the excellent outcome overall with or without CT, risk versus benefit of CT has to be taken into account (patient s age, performance status, comorbidities and preferences). METASTATIC BREAST CANCER RELATIONSHIP BETWEEN TUMOUR INFILTRATING LYMPHOCYTE (TIL) LEVELS AND RESPONSE TO PEMBROLIZUMAB IN METASTATIC TRIPLE NEGATIVE BREAST CANCER (TNBC): RESULTS FROM KEYNOTE-086 TILs have been observed in TNBC and are thought to represent pre-existing antitumor immunity. Thus, TILs could be a biomarker for response to immune checkpoint blockade. We assessed if TIL levels were associated with response to pembrolizumab monotherapy in the phase II KEYNOTE-086 study of previously treated mtnbc of any PD-L1 expression (cohort A) or previously untreated, PD-L1+ mtnbc (cohort B). 8 Stromal TILs were quantified by a single pathologist, blinded to clinical data using a published method of light microscopy of H&E stained slides obtained from tumour biopsies. PD-L1 expression was assessed using the PD-L1 IHC 22C3 pharmdx assay. Response was assessed every nine wks for twelve months, then every twelve wks (RECIST v1.1, central review). Relationships between transformed TIL levels and ORR and DCR (CR + PR + SD 24 wks) were assessed adjusted for cohort (A versus B) and biopsy site (lymph node versus non-lymph node). One hundred and ninety three of the first 222 pts enrolled had evaluable tumour samples: 147 from cohort A, 46 from cohort B. In total, 146 samples were newly collected (mostly from metastatic sites), 47 were archival (mostly from primary breast tumours). The median TIL level was higher in cohort B versus A (17.5% versus 5%), and in archival versus newly collected samples (10% versus 5%), and lymph node versus non-lymph node samples (10% versus 5%). The ORR in pts with TIL level versus < median was 6% versus 2% in cohort A and 39% versus 9% in cohort B. Median TIL level in responders versus non-responders was 10% versus 5% in cohort A and 50% versus 15% in cohort B. In the combined cohorts, higher TIL levels were associated with significantly improved ORR and DCR. PD-L1 expression significantly correlated with TIL levels. 8 TIL levels can identify pts with mtnbc with a greater chance of achieving response to pembrolizumab monotherapy, particularly in the first-line setting. TILs should be routinely assessed in primary tumours to stratify for trials using immunotherapy in breast cancer. ADAPTIVE PHASE II RANDOMISED NON- COMPARATIVE TRIAL OF NIVOLUMAB AFTER INDUCTION TREATMENT IN TNBC: FIRST RESULTS OF THE TONIC TRIAL Anti-PD-(L)1 can result in durable responses in pts with mtnbc. However, only a small subgroup of TNBC pts benefit from anti-pd-(l)1 with response rates of ± 10% in unselected cohorts. There is an urgent clinical need to identify strategies that render the tumour micro-environment more sensitive to anti-pd-(l)1therapy. Preclinical studies have shown that irradiation or low dose chemotherapy may stimulate anti-cancer immune responses. In this trial, 50 pts with mtnbc who received 3 lines of palliative chemotherapy were randomly allocated to one of five two week induction treatments consisting of: 1) 3x 8 Gy irradiation of 1 metastatic lesion or, 2) 2x doxorubicin 15 mg weekly or, 3) cyclophosphamide 50 mg daily orally or, 4) 2x cisplatin 40 mg/m² weekly or, 5) no induction treatment. After this two week induction period, all pts received nivolumab 3 mg/kg until RECIST 1.1 progression. To date, 50 pts are evaluable with a median follow-up of four months (range 1-15). Previous treatments for metastatic disease were 0, 1 or 2+ lines in 20%, 52% and 28%, respectively. The ORR is 22% with two CRs (4%) and nine PRs (18%). An additional two pts had a SD (4%), resulting in a clinical benefit rate (CR + PR + SD >24 wks) of 26%. The median duration of response was 10.9 months. Pts with higher leukocyte infiltration and CD8 T-cell counts in tumour biopsies were more likely to respond to the treatment. 9 This first study in TNBC shows that nivolumab after priming the tumour micro-environment with either irradiation or chemotherapy is feasible and results in a promising response rate that appears higher than in previous PD-(L)1 blockade monotherapy studies in unselected TNBC. OLYMPIAD: FURTHER EFFICACY OUTCOMES IN PATIENTS WITH HER2- MBC AND A GERMLINE BRCA MUTATION RECEIVING OLAPARIB MONOTHERAPY VERSUS STANDARD SINGLE-AGENT CHEMOTHERAPY TREATMENT OF PHYSICIAN S CHOICE Among pts with metastatic HER2- BC and a germline VOLUME11NOVEMBER2017
5 CONGRESS HIGHLIGHTS SPECIAL EDITION 313 FIGURE 2. PFS in the phase III MONARCH-3 trial. 12 BRCA1/2 mutation in the OlympiAD study, the ORR with olaparib was double what was seen with standard chemotherapy. The observed ORR of 59.9% with olaparib exceeded that seen in prior phase II studies, possibly owing to the previous study populations being more heavily pretreated. Importantly, the onset of response was early and similar in both treatment arms, which may be useful in symptomatic pts or in patients with rapid disease progression where a quick response is needed. Olaparib treatment also led to a larger median reduction in target lesion size compared with chemotherapy. Although the study was not powered to detect differences in treatment effects between subgroups, the PFS benefit for olaparib over chemotherapy across subgroups by metastatic location and number of metastatic sites was consistent with what was seen in the overall population. 10 The change from baseline in global health status/qol score significantly favoured pts treated with olaparib compared with chemotherapy. The time to deterioration in global health status/qol also significantly favoured pts treated with olaparib compared with chemotherapy; 64.0% of patients were deterioration-free at twelve months in the olaparib group and 53.5% in the chemotherapy. Although potentially biased by the open-label nature of the study, a longer time to subsequent cancer therapy may reflect perceived clinical benefit for pts, primarily driven by emotional and cognitive scales. 11 New trials are needed to investigate the role of PARP inhibition as consolidation treatment following chemotherapy or in combination with immunotherapy. MONARCH 3: ABEMACICLIB AS INITIAL THERAPY FOR PATIENTS WITH HR+, HER2- ADVANCED BREAST CANCER MONARCH 3 evaluates abemaciclib, an oral selective CDK4/6 inhibitor + the non-steroidal aromatase inhibitors (NSAI) anastrozole or letrozole as initial therapy for women with HR+/HER2- MBC. The study included 493 endocrine naïve pts or pts with disease relapse >12 months after (neo) adjuvant endocrine therapy and randomised them (2:1) to receive abemaciclib (150 mg, twice daily continuous schedule) or placebo, both in combination with anastrozole (1 mg daily) or letrozole (2.5 mg daily). The primary endpoint was PFS, while ORR was a key secondary objective. 12 Results of the interim analysis at 18 months showed that, compared to endocrine therapy alone, the combination of abemaciclib and endocrine therapy significantly prolonged the PFS with a hazard ratio (HR) of (median PFS: not reached with abemaciclib vs months in placebo arm; p= ) (Figure 2). In pts with measurable disease, the ORR was 59% in the abemaciclib arm versus 44% in the placebo arm. The most frequent adverse events seen with abemaciclib versus placebo were diarrhoea (81.3% vs. 29.8%), neutropenia (41.3% vs. 1.9%), and fatigue (40.1% vs. 31.7%) 12. In summary, abemaciclib plus endocrine therapy demonstrated a tolerable safety profile and was an effective initial treatment for pts with HR+/HER2- MBC, significantly improving PFS and ORR. As such, abemaciclib is the third CDK4/6 inhibitor confirming the role of this new class of agents in combination with endocrine therapy in the treat- VOLUME11NOVEMBER20177
6 314 KEY MESSAGES FOR CLINICAL PRACTICE 1. At this moment, there is no role for pan-pi3k inhibitors in the neoadjuvant treatment of ER+, HER- EBC. 2. Combined letrozole + palbociclib is not better than chemotherapy as neoadjuvant treatment in luminal EBC. 3. There is no proven additional benefit of dual endocrine blockade in the adjuvant setting of EBC. 4. Benefit from extended treatment with neratinib in high-risk ER+, HER2+ disease is confirmed. Incremental toxicity is to be considered. No data on OS yet. 5. Small node-negative tumours can be very aggressive, even if they are classified as clinical low risk. Tumour biology needs to be taken into account when deciding on adjuvant treatments in this patient population. 6. High TILs and low LDH may predict response to immunotherapy in TNBC. 7. Priming with radiotherapy or chemotherapy followed by boost with nivolumab seems an attractive strategy in TNBC. 8. The PARP inhibitor olaparib confirmed its activity in BRCA mutated MBC. 9. Abemaciclib is the third CDK4/6 inhibitor confirming the role of this new class of agents in combination with endocrine therapy in the treatment of MBC. ment of MBC. No data on OS are available yet. Median OS on letrozole alone is now approximately 50 months. Exploratory subgroup analyses suggest that pts with liver metastases had substantial benefit from the addition of abemaciclib (twelve month PFS achieved by 61.5% versus 31.4% of pts with placebo), while in some pts with a long treatment-free interval or bone-only disease (twelve month PFS 86% versus 75.7% of pts with placebo) single agent endocrine therapy may be an appropriate initial therapy. 12 REFERENCES 1. Saura C, et al. Primary results of LORELEI: a phase II randomised, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/HER2-negative early breast cancer (EBC). Presented at ESMO 2017; Abstract LBA10_PR. 2. Cottu P, et al. Letrozole and palbociclib versus 3 rd generation chemotherapy as neoadjuvant treatment of luminal breast cancer. Results of the UNICAN- CER-NeoPAL study. Presented at ESMO 2017; Abstract LBA9. 3. Ruíz-Borrego M, et al. Phase III evaluating the addition of fulvestrant (F) to anastrozol (A) as adjuvant therapy in postmenopausal women with hormone receptor positive HER2 negative (HR+/HER2-) early breast cancer (EBC): Results from the GEICAM/ study. Presented at ESMO 2017; Abstract 148O. 4. Chan A, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2016;17(3): O Martin Jimenez M, et al. Neratinib after trastuzumab (T)-based adjuvant therapy in early-stage HER2+ breast cancer (BC): 5 year analysis of the phase III ExteNET trial. 6. Delaloge S, et al. Effects of neratinib (N) on health-related quality of life (HRQoL) in early-stage HER2+ breast cancer (BC): longitudinal analyses from the phase III ExteNET trial. Presented at ESMO 2017; Abstract 177P O_PR Tryfonidis K, et al. Not all small node negative (pt1abn0) breast cancers are similar: Outcome results from an EORTC 10041/BIG 3-04 (MINDACT) trial substudy. 8. Loi S, et al. Relationship between tumour infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mtnbc): results from KEYNOTE-086. Presented at ESMO 2017; Abstract LBA Kok M, et al. Adaptive phase II randomised non-comparative trial of nivolumab after induction treatment in triple negative breast cancer: TONIC-trial. Presented at ESMO 2017; Abstract LBA Delaloge S, et al. OlympiAD: Further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy versus standard single-agent chemotherapy treatment of physician s choice. Presented at ESMO 2017; Abstract 243PD. 11. Robson M, et al. OlympiAD: Health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mbc) and a germline BRCA mutation (gbrcam) receiving olaparib monotherapy versus standard single-agent chemotherapy treatment of physician s choice (TPC). Presented at ESMO 2017; Abstract 290P. 12. Di Leo A, et al. MONARCH 3: Abemaciclib as initial therapy for patients with HR+/ HER2- advanced breast cancer. Presented at ESMO 2017; Abstract 236O_PR. VOLUME11NOVEMBER2017
BREAST CANCER SLIDE DECK 2017 Selected abstracts from:
BREAST CANCER SLIDE DECK 2017 Selected abstracts from: ESMO 2017 CONGRESS ESMO 2017 CONGRESS 8 12 September 2017 8 12 September Madrid, Spain 2017 Madrid, Spain Supported by Eli Lilly and Company. Eli
More informationAdvances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings Eve Rodler, MD University of California at Davis October 2016 17th Annual Advances in Oncology September 30-October 1, 2016
More informationClinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC)
Clinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC) Eric P Winer, MD Disclosures for Eric P Winer, MD No real or apparent conflicts of interest to disclose Key Topics: PARP and
More informationSession Breast Cancer. Alessandra Fabi Il punto di vista dell esperto
Session Breast Cancer Alessandra Fabi Il punto di vista dell esperto Roma 6-7.10.2017 The Importance of Understanding What Disease to Treat Cejalvo et al, Cancer Res 2017 Skyline Chaging at evolution of
More informationThe next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive
More informationLecture 5. Primary systemic therapy: clinical and biological endpoints
Lecture 5 Primary systemic therapy: clinical and biological endpoints Valentina Guarneri, M.D., Ph.D. Primary systemic therapy in breast cancer Firstly introduced d into clinical i l practice in 70s for
More informationUpdate on New Perspectives in Endocrine-Sensitive Breast Cancer. James R. Waisman, MD
Update on New Perspectives in Endocrine-Sensitive Breast Cancer James R. Waisman, MD Nothing to disclose DISCLOSURE TAILORx Oncotype Recurrence Score TAILORx Study Design Sparano, J Clin Oncol 2008;26:721-728
More informationASCO 2017 BREAST CANCER HIGHLIGHTS
Post-ASCO 24 th June 2017, Dolce La Hulpe, Belgium ASCO 2017 BREAST CANCER HIGHLIGHTS Martine J. Piccart-Gebhart, MD, PhD Jules Bordet Institute, Brussels, Belgium Université Libre de Bruxelles Breast
More informationBreast Cancer: ASCO Poster Review
Breast Cancer: ASCO Poster Review Carmen Criscitiello, MD, PhD Istituto Europeo di Oncologia Milano HER2+ SUBTYPE Research questions in early HER2+ BC De-escalation of toxicity without compromising efficacy
More informationBreast cancer treatment
Report from the San Antonio Breast Cancer Symposium Breast cancer treatment Determining the best options for select patient groups Sara Soldera, MD, Resident; Nathaniel Bouganim, MD, FRCPC, Medical Oncologist;
More informationTargeting CDK 4/6. Jee Hyun Kim, M.D., Ph.D. Seoul National University College of Medicine
2016.04.30 GBCC Education Symposium Targeting CDK 4/6 Jee Hyun Kim, M.D., Ph.D. Seoul National University College of Medicine Contents Cyclins -CDKs in cell cycle control CDK 4/6 in breast cancer Preclinical
More informationXII Michelangelo Foundation Seminar
XII Michelangelo Foundation Seminar The opportunity of the neoadjuvant approach L. Gianni, Milan, I XII Michelangelo Foundation Seminar Milano, October 12, 2012 The opportunity of the neoadjuvant approach
More informationSummary... 2 MELANOMA AND OTHER SKIN TUMOURS... 3
ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 MELANOMA AND OTHER SKIN TUMOURS... 3 Long-term results show adjuvant therapy with ipilimumab improves OS in high
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationSesiones interhospitalarias de cáncer de mama. Revisión bibliográfica 4º trimestre 2015
Sesiones interhospitalarias de cáncer de mama Revisión bibliográfica 4º trimestre 2015 Selected papers Prospective Validation of a 21-Gene Expression Assay in Breast Cancer TAILORx. NEJM 2015 OS for fulvestrant
More informationTriple Negative Breast cancer New treatment options arenowhere?
Triple Negative Breast cancer New treatment options arenowhere? Ofer Rotem, M.D., B.Sc. Breast Unit, Davidoff center Rabin Medical center October 2017 Case 6/2013 - M.D., 38 years old woman, healthy, no
More informationImmunotherapy for Breast Cancer Clinical Development
Immunotherapy for Breast Cancer Clinical Development Laurence Buisseret, MD, PhD Breast Cancer Translational Research Laboratory Institut Jules Bordet Université Libre de Bruxelles (ULB) ESMO preceptorship
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationOpen Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD
Open Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD Hanahan and Weinberg, 2000 Acquired Capabilities of Cancer Clinical Trials When should I consider a clinical trial? How do I find the right
More informationBREAST CANCER SLIDE DECK 2017 Selected abstracts from:
BREAST CANCER SLIDE DECK 2017 Selected abstracts from: 2017 ASCO ANNUAL MEETING 2 6 June 2017 Chicago, USA Supported by Eli Lilly and Company. Eli Lilly and Company has not influenced the content of this
More informationOvercoming resistance to endocrine or HER2-directed therapy
Overcoming resistance to endocrine or HER2-directed therapy Jane Lowe Meisel, MD Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute at Emory University 1 Background While most
More informationPost-ESMO 2012: Tamara Rordorf Klinik für Onkologie UniversitätsSpital Zürich T.Rordorf, SAMO Luzern 1
Post-ESMO 2012: Breast Cancer Tamara Rordorf Klinik für Onkologie UniversitätsSpital Zürich 1 Neoadjuvant treatment (in Her-2 positive disease) neoadjuvant trials abstracts: breast sparing surgery, biomarkers,
More informationTriple Negative Breast Cancer
GASCO 2016 San Antonio Breast Cancer Symposium Review Triple Negative Breast Cancer Amelia Zelnak, MD, MSc Atlanta Cancer Care Northside Hospital Cancer Institute Disclosures: consultant for Novartis,
More informationOutline of the presentation
Outline of the presentation Breast cancer subtypes and classification Clinical need in estrogen-positive (ER+) metastatic breast cancer (mbc) Sulforaphane and SFX-01: the preclinical evidence STEM Phase
More informationEvolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents
Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Kimberly L. Blackwell MD Professor Department of Medicine and Radiation Oncology Duke University Medical Center
More informationUpdate in the treatment of Her2- overexpressing breast cancers. Fabrice ANDRE Institut Gustave Roussy Villejuif, France
Update in the treatment of Her2- overexpressing breast cancers Fabrice ANDRE Institut Gustave Roussy Villejuif, France Questions Should tumors
More informationNew Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer
New Evidence reports on presentations given at ASCO 2012 New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer Presentations at ASCO 2012 Breast
More informationESMO Preceptorship Breast Cancer. Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Early Drug Development Istituto Europeo di Oncologia
ESMO Preceptorship Breast Cancer Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Early Drug Development Istituto Europeo di Oncologia Outline Rational for immune-based therapy in BC How to
More informationMetastatic breast cancer: sequence of therapies
Metastatic breast cancer: sequence of therapies Clinical Case Discussion Nadia Harbeck, MD PhD Breast Center, Department of Gynecology and Obstetrics University of Munich, Ludwig-Maximilians University
More informationImmunotherapy in breast cancer. Carmen Criscitiello, MD, PhD European Institute of Oncology Milan, Italy
Immunotherapy in breast cancer Carmen Criscitiello, MD, PhD European Institute of Oncology Milan, Italy Outline Rational for immune-based therapy in breast cancer Immunogenic chemotherapy Targeting immune
More informationRIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO. Dra. Elena Aguirre H.U. Miguel Servet
RIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO Dra. Elena Aguirre H.U. Miguel Servet INTRODUCTION ADVANCED BREAST CANCER HR+/HER2- YES Consider Chemo VISCERAL CRISIS? NO Endocrine Therapy X3 Toxicity Progresive
More informationTNBC: What s new Déjà vu All Over Again? Lucy R. Langer, MD MSHS Compass Oncology - SABCS 2016 Review February 21, 2017
TNBC: What s new Déjà vu All Over Again? Lucy R. Langer, MD MSHS Compass Oncology - SABCS 2016 Review February 21, 2017 The problem with TNBC 1. Generally more aggressive 2. ONLY chemotherapy 3. No other
More informationWhen is Chemotherapy indicated in Advanced Luminal Breast Cancer?
When is Chemotherapy indicated in Advanced Luminal Breast Cancer? Soo-Chin Lee Head & Senior Consultant Department of Haematology-Oncology Clinical Care National University Cancer Institute, Singapore
More informationWhat is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland
What is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland Outline Early breast cancer Advanced breast cancer Open questions Outline Early breast cancer
More informationBest of San Antonio 2008
Best of San Antonio 2008 Ellie Guardino, MD/PhD Assistant Professor Stanford University BIG 1 98: a randomized double blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant
More informationBreast Cancer Immunotherapy. Leisha A. Emens, MD PhD Johns Hopkins University Bloomberg Kimmel Institute for Cancer Immunotherapy
Breast Cancer Immunotherapy Leisha A. Emens, MD PhD Johns Hopkins University Bloomberg Kimmel Institute for Cancer Immunotherapy Conflict of Interest I have the following financial relationships to disclose:
More informationA vision for HER2 future
School of Medical Oncology Department of Medical and Biological Sciences - University of Udine Department of Oncology - University Hospital of Udine A vision for HER2 future Current therapeutic algorithm
More informationRecent Update in Management of Breast Cancer: Medical Oncology. Jin Hee Ahn, M.D., PhD. 23-April-2015
2015 GBCC & 4 th IBCS 1/37 Recent Update in Management of Breast Cancer: Medical Oncology Jin Hee Ahn, M.D., PhD. 23-April-2015 Department of Oncology, Asan Medical Center, UUCM, Seoul, Korea 2/37 3/37
More informationHighlights of. Metastatic & Advanced Breast Cancer
Highlights of Metastatic & Advanced Breast Cancer 1 Financial Disclosure(s) I currently have or have had the following relevant financial relations to disclose: Speaker s Bureau: Novartis 2 Off Label Use
More informationGene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA
Gene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA When Are Biomarkers Ready To Use? Same Rules for Gene Expression Panels Key elements
More informationNeo-adjuvant and adjuvant treatment for HER-2+ breast cancer
Neo-adjuvant and adjuvant treatment for HER-2+ breast cancer Angelo Di Leo «Sandro Pitigliani» Medical Oncology Unit Hospital of Prato Istituto Toscano Tumori Prato, Italy NOAH: Phase III, Open-Label Trial
More informationPredicting outcome in metastatic breast cancer
Predicting outcome in metastatic breast cancer Aleix Prat, MD, PhD Medical Oncology Department Translational Genomics and Targeted Therapeutics in Solid Tumors Monday, 15 th January, Manchester, UK Disclosures
More informationESMO 2017, Madrid, Spain Dr. Loredana Vecchione Charite Comprehensive Cancer Center, Berlin HIGHLIGHTS ON CANCERS OF THE UPPER GI TRACT
ESMO 2017, Madrid, Spain Dr. Loredana Vecchione Charite Comprehensive Cancer Center, Berlin HIGHLIGHTS ON CANCERS OF THE UPPER GI TRACT DOCETAXEL, OXALIPLATIN AND FLUOROURACIL/LEUCOVORIN (FLOT) FOR RESECTABLE
More informationDieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
What is hot in breast cancer brain metastases? Dieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands 8th Annual Brain Metastases Research and Emerging Therapy
More informationCLINICAL TRIALS ACC. Jul 2016
CLINICAL TRIALS ACC Jul 2016 Glioblastoma BRAIN A071102 A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
More informationCancers du Sein Métastatiques
Cancers du Sein Métastatiques Véronique Diéras Journée Laurence Leroyer Rennes 18 mai 2018 Plan ESME Inhibiteurs CDK 4/6 RH+ Inhibiteurs PARP Anticorps drogue-conjugués Perspectives 2018-2019 ESME Time
More informationTRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer
TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer Marta Bonotto Department of Oncology University Hospital of Udine TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive
More informationTerapia adiuvante con inibitori delle Kinasi Cliclina Dipendenti 4/6: quale futuro? Filippo Montemurro
Terapia adiuvante con inibitori delle Kinasi Cliclina Dipendenti 4/6: quale futuro? Filippo Montemurro Unit of Investigative Clinical Oncology Istituto di Candiolo (IRCCS) Disclosures Speaker s Honoraria
More informationWhat to do after pcr in different subtypes?
What to do after pcr in different subtypes? Luca Moscetti Breast Unit Università degli Studi di Modena e Reggio Emilia Policlinico di Modena, Italy Aims of neoadjuvant therapy in breast cancer Primary
More informationPost-ASCO 2017 Cancer du sein Triple Négatif
Post-ASCO 217 Cancer du sein Triple Négatif A.Ladjeroud, K.Bouzid Centre Pierre et Marie Curie- Alger Oran, 3 Septembre 217 Phase III Investigation of Neoadjuvant Carboplatin ± Veliparib in Combination
More information2014 San Antonio Breast Cancer Symposium Review
2014 San Antonio Breast Cancer Symposium Review HER2 Positive Disease 01-10-2015 Elisavet Paplomata, MD Assistant Professor Hematology & Medical Oncology Emory University Winship Cancer Institute S6-01
More informationManagement of Triple Negative Breast Cancer. Giuseppe Curigliano MD, PhD University of Milano and European Institute of Oncology
Management of Triple Negative Breast Cancer Giuseppe Curigliano MD, PhD University of Milano and European Institute of Oncology Outline Heterogeneity of TNBC Targeting TNBC by subtypes New antibody drug
More information38 years old, premenopausal, had L+snbx. Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI %
38 years old, premenopausal, had L+snbx Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI67 5-10% Question: What will you do now? 1. Give adjuvant chemotherapy 2. Send for Oncotype
More informationDR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID
DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID RESUMEN DE ARTICULOS THERESA BOLERO 3 NOAH UP-DATE GEPAR SIXTO RADIOTHERAPY EBCTCG CTCs MISCELANEAS Lancet Oncol 2014;
More informationSustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA
Sustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA The fascinating history of Herceptin 1981 1985 1987 1990 1992 1998 2000 2005 2006 2008 2011 Murine
More informationDennis J Slamon, MD, PhD
I N T E R V I E W Dennis J Slamon, MD, PhD Dr Slamon is Professor of Medicine, Chief of the Division of Hematology/Oncology and Director of Clinical and Translational Research at UCLA s David Geffen School
More informationKarcinom dojke. PANEL: Semir Bešlija, Zdenka Gojković, Robert Šeparović, Tajana Silovski
Karcinom dojke PANEL: Semir Bešlija, Zdenka Gojković, Robert Šeparović, Tajana Silovski MBC: HER2 PHEREXA: Study Design Multicenter, randomized, open-label phase III trial Stratified by prior CNS disease,
More informationSystemic Therapy of HER2-positive Breast Cancer
Systemic Therapy of HER2-positive Breast Cancer Tanja Cufer, MD, PhD University Clinic Golnik, Medical Faculty Ljubljana, Slovenia ESO ESMO Masterclass, Belgrade 2018 HER2-positive Breast Cancer Adjuvant
More information14,30 18,20. II Sessione. Moderatori: Giovanni Apolone, Roberto Labianca
14,30 18,20 II Sessione Moderatori: Giovanni Apolone, Roberto Labianca 14,30 14,50 Ca mammario: attualità e prospettive di ricerca Luca Livraghi Carcinoma mammario: attualità e prospettive di ricerca LUCA
More informationManejo do câncer de mama RH+ na adjuvância: o que há de novo?
II Simpósio Internacional de Câncer de Mama para o Oncologista Clínico Manejo do câncer de mama RH+ na adjuvância: o que há de novo? INGRID A. MAYER, MD, MSCI Assistant Professor of Medicine Director,
More informationUK Interdisciplinary Breast Cancer Symposium. Should lobular phenotype be considered when deciding treatment? Michael J Kerin
UK Interdisciplinary Breast Cancer Symposium Should lobular phenotype be considered when deciding treatment? Michael J Kerin Professor of Surgery National University of Ireland, Galway and Galway University
More informationCáncer de mama HER2+/RE+ vs HER2+/RE : Una misma enfermedad? Dra E. Ciruelos Departamento de Oncología Médica Hospital Universitario 12 de Octubre
Cáncer de mama HER2+/RE+ vs HER2+/RE : Una misma enfermedad? Dra E. Ciruelos Departamento de Oncología Médica Hospital Universitario 12 de Octubre Recurrence of HER2-positive breast cancer (A) Time to
More information6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017
TARGETING THE TARGETS IN 2017 Primary Care Focus Symposium July 1, 2017 Grace Wang MD I do not have any relevant financial relationships to disclose at this time TARGETING THE TARGETS IN 2017 What are
More informationEARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY. Dr. Carlos Garbino
EARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY Dr. Carlos Garbino EARLY BREAST CANCER ADJUVANT CHEMOTHERAPY SUSTANTIVE DIFFICULTIES FOR A WORLDWIDE APPLICABILITY DUE TO IMPORTANT INEQUALITIES + IN DIFFERENT
More informationTriple-Negative Breast Cancer
June 2017 Triple-Negative Breast Cancer Amir Sonnenblick, MD, PhD Sharett institute of oncology Hadassah-Hebrew university medical center, Jerusalem, Israel This presentation is the intellectual property
More informationTreatment of Metastatic Breast Cancer. Prof RCCoombes Imperial College London
Treatment of Metastatic Breast Cancer Prof RCCoombes Imperial College London Metastatic Breast Cancer: General Guidelines Specialized oncology nurses (if possible specialized breast nurses) should be part
More informationPrincipales presentaciones de AstraZeneca/MedImmune en el congreso de ESMO 2017
Principales presentaciones de AstraZeneca/MedImmune en el congreso de ESMO 2017 Autor principal Título del abstract Detalles de la presentación Cáncer de pulmón Paz-Ares L Ramalingam S Zhou C PACIFIC:
More informationBiomarkers for HER2-directed Therapies : Past Failures and Future Perspectives
Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives Ian Krop Dana-Farber Cancer Institute Harvard Medical School Inchon 2018 Adjuvant Trastuzumab Improves Outcomes in HER2+ Breast
More informationTerapia sistemica neoadiuvante: in quali tumori? Quali risultati? Dott. Giacomo Pelizzari
Terapia sistemica neoadiuvante: in quali tumori? Quali risultati? Dott. Giacomo Pelizzari Neoadjuvant Treatment A window of opportunity Rational: Historically proposed to enable breast-conserving surgery
More informationReview of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012
Review of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012 Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology, Emory
More informationSystemic Therapy of HER2-positive Breast Cancer
Systemic Therapy of HER2-positive Breast Cancer Tanja Cufer, MD, PhD University Clinic Golnik, Medical Faculty Ljubljana, Slovenia ESO ESMO Masterclass, Belgrade 2017 Relative Risk HER2-positive Breast
More informationExpanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer
Expanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer Sara A. Hurvitz, MD, FACP Associate Professor of Medicine University of California Los Angeles Los Angeles, California Trastuzumab
More informationNovel Preoperative Therapies for HER2-Positive Breast Cancer. Debu Tripathy, MD University of Southern California Norris Comprehensive Cancer Center
Novel Preoperative Therapies for HER2-Positive Breast Cancer Debu Tripathy, MD University of Southern California Norris Comprehensive Cancer Center Key Findings to Date in the Neoadjuvant Therapy of HER2+
More informationJosé Baselga, MD, PhD
i n t e r v i e w José Baselga, MD, PhD Dr Baselga is Physician-in-Chief at Memorial Sloan-Kettering Cancer Center in New York, New York. Tracks 1-15 Track 1 Track 2 Track 3 Track 4 Track 5 Track 6 Track
More informationInibitori delle chinasi ciclino dipendenti nel trattamento della malattia metastatica HR-positiva Gli studi clinici
Inibitori delle chinasi ciclino dipendenti nel trattamento della malattia metastatica HR-positiva Gli studi clinici Laura Orlando UOC Oncologia & Breast Unit Brindisi Verona 22/04/2016 Summary Studi con
More informationGeneral Information, efficacy and safety data
Horizon Scanning in Oncology Horizon Scanning in Oncology 29 th Prioritization 4 th quarter 2016 General Information, efficacy and safety data Nicole Grössmann Sarah Wolf Claudia Wild Please note: Within
More informationBreast : ASCO Abstracts for Review
Breast : ASCO 2011 Susana Campos, MD, MPH Dana Farber Cancer Institute Abstracts for Review Prevention Neoadjuvant Metastatic Brain mets LBA 504: Exemestane for primary prevention of breast cancer in postmenopausal
More informationEvolving Insights into Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Evolving Insights into Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic
More informationMetastatic Breast Cancer What is new? Subtypes and variation?
Metastatic Breast Cancer What is new? Subtypes and variation? Anne Blaes, MD, MS University of Minnesota, Division of Hematology/Oncology Director, Adult Cancer Survivor Program Current estimates for metastatic
More informationTriple Negative Breast Cancer: Part 2 A Medical Update
Triple Negative Breast Cancer: Part 2 A Medical Update April 29, 2015 Tiffany A. Traina, MD Breast Medicine Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College Overview What is
More informationConsiderations in Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Considerations in Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic Treatment
More informationClaudio Zamagni Milano 16 giugno 2018 AIOM Post-ASCO BREAST CANCER HIGHLIGHTS ASCO 2018
Claudio Zamagni Milano 16 giugno 2018 AIOM Post-ASCO BREAST CANCER HIGHLIGHTS ASCO 2018 (Neo)Adjuvant Advanced De-escalation ER+ve HER2 ve Node ve TAILORx HER2 +ve Persephone PerElisa PARPi in gbrcam HER2
More informationSystemic therapy: HER-2 update. Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven
Systemic therapy: HER-2 update Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven New drugs Strategic issues Specific anti-her2 drugs Lapa$nib /Nera$nib Baselga & Swain,
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationRecent advances in the management of metastatic breast cancer in older adults
Recent advances in the management of metastatic breast cancer in older adults Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Important recent advances in the
More informationTriple negative breast cancer -neoadjuvant and adjuvant systemic therapy
Triple negative breast cancer -neoadjuvant and adjuvant systemic therapy Sung-Bae Kim, MD, PhD Department of Oncology Asan Medical Center University of Ulsan College of Medicine Seoul, Korea DISCLOSURE
More informationThe Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now?
1 The Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now? Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program
More informationXII Michelangelo Foundation Seminar
XII Michelangelo Foundation Seminar Paradigm shift? The Food and Drug Administration collaborative project P. Cortazar, Silver Spring, USA FDA Perspective: Moving from Adjuvant to Neoadjuvant Trials in
More informationUpdates From San Antonio Breast Cancer Symposium 2017
Updates From San Antonio Breast Cancer Symposium 2017 Rob Coleman University of Sheffield Presentation Outline New Insights into adjuvant endocrine treatment Duration of treatment Perioperative therapy
More informationOverview and future horizons of PARP inhibitors in BRCAassociated. Judith Balmaña
Overview and future horizons of PARP inhibitors in BRCAassociated breast cancer Judith Balmaña PARP inhibitors: Mechanism of action Clinical development: Monotherapy In combination with chemotherapy Ongoing
More informationEmerging Strategies in Triple-Negative Breast Cancer
Expert Review in Immunotherapy in Breast Cancer Emerging Strategies in Triple-Negative Breast Cancer Reference Slide Deck Is Breast Cancer Immunogenic? Recent proof that breast cancer may elicit an immune
More informationSYSTEMIC TREATMENT OF TRIPLE NEGATIVE BREAST CANCER
SYSTEMIC TREATMENT OF TRIPLE NEGATIVE BREAST CANCER Sunil Shrestha 1*, Ji Yuan Yang, Li Shuang and Deepika Dhakal Clinical School of Medicine, Yangtze University, Jingzhou, Hubei Province, PR. China Department
More informationOptimizing anti-her-2 therapies for ABC Potential role of immunotherapy. Javier Cortes, Ramon y
Optimizing anti-her-2 therapies for ABC Potential role of immunotherapy Javier Cortes, Ramon y Cajal University Hospital, Madrid, Spain Vall d Hebron Institute of Oncology (VHIO), Medica Scientia Innovation
More informationClinical Management Guideline for Breast Cancer
Initial Evaluation Clinical Stage Pre-Treatment Evaluation Treatment and pathological stage Adjuvant Treatment Less than 4 positive lymph nodes ER Positive HER2 Negative (see page 2 & 3 ) Primary Diagnosis:
More informationWilliam J. Gradishar MD
Northwestern University Feinberg School of Medicine Adjuvant Endocrine Therapy For Postmenopausal Women SOBO 2013 William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationImmunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know
Immunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know Jeffrey Weber, MD, PhD Laura and Isaac Perlmutter Cancer Center NYU Langone Medical Center New York, New York What Is the Current
More informationEARLY BREAST CANCER, HER2-POSITIVE
EARLY BREAST CANCER, HER2-POSITIVE CLINICAL CASE DISCUSSION Elżbieta Senkus Medical University of Gdańsk Gdańsk, Poland esmo.org DISCLOSURES Honoraria: Amgen, Astellas, AstraZeneca, Bayer, BMS, Celgene,
More informationThe Expert Thoughts. Alessandra Fabi Oncologia Medica 1
The Expert Thoughts Alessandra Fabi Oncologia Medica 1 My Thoughts Neoadjuvant: from the lessons of the history Adjuvant: Escalation and De-escalation Advanced and HER2+ : field for immunomodulation Brain
More informationSummary... 2 GENITOURINARY TUMOURS - PROSTATE... 3
ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 GENITOURINARY TUMOURS - PROSTATE... 3 Custirsen provides no additional survival benefit to cabazitaxel/prednisone
More information